Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer%26apos;s Disease from Other Dementia Disorders

作者：Nutu Magdalena^*; Zetterberg Henrik; Londos Elisabet; Minthon Lennart; Nagga Katarina; Blennow Kaj; Hansson Oskar; Ohrfelt Annika

来源：Dementia and Geriatric Cognitive Disorders, 2013, 36(1-2): 99-110.

DOI：10.1159/000353442

• Amyloid-beta
• Alzheimer%26apos
• s disease
• Parkinson%26apos
• s disease
• Immunoassays
• Amplified luminescent proximity homogenous immunoassay

Background: The well-established core biomarkers used to identify Alzheimer%26apos;s disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson%26apos;s disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson%26apos;s disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB.

• 出版日期2013